• Patient recruitment has begun for the Multiple Myeloma study
• Net sales amounted to MSEK 0,0 (0,0)
• Operating profit/loss amounted to MSEK -1,6 (-1,1)
• Earnings per share* SEK -0.08 (-0.06)

* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 18,485,857. Amounts in brackets refer to the corresponding period last year.

• Net sales amounted to MSEK 0,0 (0,0)
• Operating profit/loss amounted to MSEK -3,7 (-3,2)
• Earnings per share* SEK -0.19 (-0.20)
• Cash and cash equivalents at the end of the period amounted to MSEK 27.1 (35,5)

* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 16,225,200. Amounts in brackets refer to the corresponding period last year.

CEO's comment

The application for clinical phase 1 study regarding OsteoDex's treatment of multiple myeloma was approved by the Medical Products Agency and permission was granted on August 10, 2022. The study includes 20 patients with multiple myeloma and is conducted at about 4 hospital centers in Sweden.

The principal investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University Hospital, Huddinge. The main blood markers will be analyzed at the Central Laboratory, Karolinska University Hospital, NKS, Solna. Patients included have relapsed/refractory disease and have received 1-3 prior lines of therapy. The primary objective is to confirm safety and tolerability and as a secondary objective to determine treatment response documented by change in the level of disease-related biomarkers. Documentation of quality of life will also be done (QoL scores).

Study material, GMP manufactured OsteoDex, is produced by Biovian OY, Turku, Finland. Biovian is the company's CMO. The study has started at the end of March 2023 and patient recruitment is ongoing.  It is expected to be completed in Q4 2024.

Anders R Holmberg
CEO

Contact

Anders Holmberg, CEO, +46 73 324 27 82

Gösta Lundgren, CFO, +46 70 710 47 88

This information is such information that DexTech Medical AB is required to disclose in accordance with the EU Market Abuse Regulation. The information was submitted for publication on April 28, 2023 through the care of the above contact persons.

This report is an in-house translation of the original report in Swedish

Stockholm April 28, 2023
DexTech Medical AB
Board of Directors

This report has not been reviewed by the Company's auditor.

DexTech Medical AB
Dag Hammarskjölds Väg 34A, Uppsala
Mailing address:
Box 389, 751 06 Uppsala
www.dextechmedical.com

DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. A successful clinical phase II study has been conducted with OsteoDex where the results show high tolerability with mild side effects and treatment effect on patients who fail on existing drugs. DexTech's goal is to outlicense each drug candidate no later than after the completed phase II study. DexTech Medical AB is listed on Spotlight Stock Market.